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(HD vs. PD), cause of dropout (death, transfer, transplant, lostEffect of cause and time of dropout on the residual GFR: A
to follow-up/study ended), and time to dropout. The modelcomparative analysis of the decline of GFR on dialysis.
allowed a comparison of the starting GFR and the rate of declineBackground. The decline of residual renal function (RRF)
in GFR between PD and HD adjusting for these three factors.on dialysis has been reported to be slower in peritoneal dialysis
Results and Conclusions. The results of our analysis suggest(PD) then hemodialysis (HD). However, some clinicians have
that such informative censoring is independent of treatmentquestioned whether this reported difference might not be
modality and that even after correcting for dropout caused bycaused by selection bias. In particular, if continuous ambulatory
death or transfer to another modality, patients starting on PDPD (CAPD) delivers only marginally adequate therapy as some
have a lower rate of decline in GFR (that is, better preservationclinicians speculate, then perhaps those patients on CAPD with
of GFR) than patients starting on HD.low glomerular filtration rate (GFR) are purposefully switched
to HD. If true, transferring CAPD patients with low GFR to
HD could create a selection bias that very well may account
for the differences in GFR between PD and HD. This is particu- A natural progression of the disease process in patients
larly problematic if one then censors patients at the time of
with chronic renal failure often leads to an inexorabletransfer from PD to HD from analysis (that is, patients are no
decline in residual renal function (RRF), eventually lead-longer followed in the study once they have switched treatment
modalities). When this occurs, the data are said to be informa- ing to either dialysis or transplantation. A residual renal
tively censored, a term used by statisticians to describe any creatinine clearance (CCr) of 1 mL/min translates into a
kind of systematic bias associated with censored or incomplete weekly CCr of 10 L. It is obvious that the contributiondata. In particular, informative censoring occurs when patients of RRF to overall small solute and water clearance iswho die or transfer to another modality very early have an
important during the initial years of dialysis, both inassociated lower starting GFR or higher rate of decline of GFR
achieving adequacy targets and maintaining appropriatethan patients who either complete the study or who die or trans-
fer much later. If patient dropout is indeed related to the rate fluid balance. Regardless of the mode of dialysis, that
of decline in GFR and if this relationship differs between PD is, hemodialysis (HD) or peritoneal dialysis (PD), there
and HD but is ignored in the analysis, then the results of such is usually an exponential decline in RRF with time.analysis may be biased.
There have been many reports dealing with the preser-Methods. This article analyzes the decline in GFR among
vation of glomerular filtration rate (GFR) and/or CCr in141 incident dialysis patients (39 HD and 102 PD) undergoing
either HD or PD at the University of Missouri-Columbia. The chronic renal failure both before and after the initiation
decline in GFR was modeled as a nonlinear function of time, of dialysis [1–16]. A comparative analysis of RRF be-
taking into account the possibility that missing values of GFR tween HD and PD patients is quite complex. The effects
may be associated with patient dropout (death, transfer to
of confounding factors like case-mix, associated comor-another modality, or transplantation). To safeguard against this
bidity, use of nephrotoxic drugs, and hemodynamic fac-possibility, we utilized a conditional nonlinear mixed-effects
model. The model was used to fit and compare each patient’s tors may influence the rate of decline of GFR. In HD, the
GFR data to time adjusting for the patient’s treatment modality type of membrane used in dialysis (biocompatible or bio-
incompatible) may influence the decline of GFR and
therefore influence a comparative analysis of the two mo-Key words: residual renal function, informative censoring, peritoneal
dalities. It is therefore possible that some or all of thesedialysis, hemodialysis, CAPD, progressive renal disease, glomerular
filtration rate. factors may introduce a bias when comparisons are made
between these two different modalities of dialysis.Received for publication February 10, 2000
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clinicians have questioned whether this reported differ- 11.44 mL/min, and on April 30, 1995, the patient was
transplanted. This patient’s unusual history had a sig-ence might not be caused by selection bias. In particular,
if continuous ambulatory PD (CAPD) delivers only mar- nificant impact on the regression estimates and was
therefore deemed an outlier and removed from all subse-ginally adequate therapy as some clinicians speculate,
then perhaps those patients on CAPD with low GFR quent analyses. The second patient was on PD with an
initial GFR of 2.50 mL/min on October 9, 1989. He thenare purposefully switched to HD. If true, transferring
CAPD patients with low GFR to HD could create a had three consecutive 24-hour urine collections with 0
urine volume reported. Following these three consecu-selection bias that very well may account for the differ-
ences in GFR between PD and HD. This is particularly tive 0 GFR values, the patient had a recorded GFR of
5.49 mL/min (March 18, 1997) just prior to dying on Aprilproblematic if one then censors patients at the time of
transfer from PD to HD from analysis (that is, patients 9, 1997. This patient likewise influenced the regression
estimates and was therefore excluded from all subse-are no longer followed in the study once they have
switched treatment modalities). When this occurs, the quent analyses.
Consequently, the analyses summarized in this articledata are said to be informatively censored, a term used
by statisticians to describe any kind of systematic bias are restricted to the remaining 39 HD and 102 PD pa-
tients. There were no patients with a baseline measureassociated with censored or incomplete data. In particu-
lar, informative censoring occurs when patients who die of 0 for GFR, and thus, all 141 of the remaining patients
were included in the analysis. The selection of PD andor transfer to another modality very early have associ-
ated with them a lower starting GFR or a higher rate of HD patients in this study was made on the basis of
different criteria, and this could affect the results anddecline of GFR than patients who either complete the
study or who die or transfer much later. If patient drop- interpretation of our findings (Discussion section). In
particular, all PD patients starting dialysis between Julyout is indeed related to the rate of decline in GFR and
if this relationship differs between PD and HD but is 1989 and June 1997 were eligible for inclusion into this
study. Follow-up on GFR was through March 3, 1998.ignored in the analysis, then the results of such analysis
In the PD patients, the urine collection was made for anmay be biased. In contrast, when the rate of decline in
average of 24 hours (1433 6 5.35 minutes, mean 6 SEM).GFR is independent of patient dropout or, vice versa,
In patients on HD, urine was collected during the interdi-patient dropout is independent of GFR, then subsequent
alytic period (2813 6 71.06 minutes).missing values of GFR are said to be missing at random,
All PD patients in our unit undergo serial measure-and we can safely ignore the fact that there are missing
ment of RRF as part of routine clinical practice anddata in the analysis.
hence were included in the study. However, in HD pa-We have recently demonstrated the presence of infor-
tients, such a practice is not routine, and serial measure-mative censoring as it applies to the decline in GFR
ments of RRF could only be done in those patients whoamong PD patients [17]. In an effort to compare the rate
gave an informed consent. Therefore, unlike the PDof decline of GFR in patients on PD versus HD, we have
patients, only those HD patients were included who gaveanalyzed the GFR data of dialysis patients from the
informed consent to participate in this study. By way ofUniversity of Missouri-Columbia (Columbia, MO, USA)
comparison, these HD patients started dialysis betweenusing a conditional nonlinear mixed-effects model. Spe-
August 1989 and February 1996 and had GFR follow-cifically, we used an exponential decay model to fit GFR
up data through March 1997. Between 1989 and 1996,as a nonlinear function of time, taking into account the
the target Kt/V (per session) for HD patients at our unit,possibility that missing values of GFR may be associated
like other units, evolved from 1.0 to 1.2. The mean bloodwith patient dropout (death, transfer to another modal-
flow was 370 mL/min (range 300 to 450 mL/min). Theity, or transplantation).
mean dialysis per session was 3.4 hours, with a range of
3.0 to 4.5 hours. Sixty-seven percent of patients were
METHODS dialyzed using cellulosic membranes. The remaining pa-
Longitudinal data on GFR were obtained on 40 HD tients were dialyzed using synthetic (polymethylmetha-
and 103 PD patients from the University of Missouri- crylate or polysulfone) membranes. The number of re-
Columbia (GFR was measured as the mean of urea and uses per dialyzer ranged between 5 and 20 during the
CCr). However, we excluded two patients from the analy- study period. In the earlier part of the study, formalde-
sis as outliers. The first patient was on HD with initial hyde was used for sterilization of the dialyzers. From
GFR of 13.4 mL/min (measured on July 8, 1991). His the beginning of 1994, glutaraldehyde was used for steril-
next GFR was 1.31 mL/min (October 11, 1991). Between ization of the dialyzers.
October 11, 1991, and December 9, 1992, this patient To determine whether the PD and HD patients were
had GFR levels ranging from 0.66 to 6.24 mL/min. On similar, we compared their baseline demographics using
either a Student t test for continuous data or a PearsonMarch 10, 1993, the reported GFR for this patient was
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Table 2. Patient demographics at baselineTable 1. Patient demographics at baseline (except for outcome)
HD % PD % HD (N 5 39) PD (N 5 102)
Variable (N 5 39) (N 5 102) P value
Variable Mean SD Mean SD P value
Sex % male 56.4 53.9 NS
Age 61.5 16.7 61.4 12.3 NSRace NS
Height cm 170.0 10.6 167.6 10.5 NSBlack 10.3 3.9
Weight kg 72.3 19.8 76.5 16.3 NSWhite 89.7 95.1
BSA m2 1.82 0.25 1.85 0.21 NSOriental 0.0 1.0
TBW L 37.2 8.8 37.9 7.1 NSCause of ESRD 0.02
24-hour urine volume mL 889.9 574.4 773.9 569.2 NSDiabetes 30.8 50.0
Baseline GFR mL/min 4.2 2.2 5.1 3.7 NSHypertension 28.2 10.8
Other 41.0 39.2 Abbreviations are: HD, hemodialysis; PD, peritoneal dialysis; BSA, body
surface area; TBW, total body water; GFR, glomerular filtration rate; NS, notPatient outcome NS
significant.Lost to follow-up 30.8 26.5
Death 35.9 43.1
Transfer modality 7.7 19.6
Transplant 25.6 10.8
Abbreviations are: HD, hemodialysis; PD, peritoneal dialysis; ESRD, end- techniques described in Vonesh and Chinchilli were used
stage renal disease; NS, not significant.
to fit the data assuming that the starting GFR, b0i, varies
randomly from patient to patient [18]. The model was
used to fit and compare each patient’s GFR data to time
adjusting for the patient’s treatment modality (HD vs.chi-square test for discrete categorical data. The results,
which are summarized in Tables 1 and 2, indicate the PD), cause of dropout (death, transfer, transplant, lost
to follow-up/study ended), and time to dropout. TheHD patients were less likely to have diabetes and more
likely to have hypertension as their primary cause of model allowed us to compare the starting GFR and the
rate of decline in GFR between PD and HD, adjustingend-stage renal disease (ESRD; P 5 0.02). Moreover,
because of limited follow-up, none of the 39 HD patients for these three factors. Data also included demographic
information on age, gender, race, and primary diagnosiswere observed to have a 0 GFR follow-up value. By
comparison, 15 of the 102 PD patients were observed to of ESRD. We included this information in the nonlinear
regression to see whether GFR is associated with anyhave a 0 GFR follow-up value (HD 0 out of 39 vs. PD
15 out of 102, P 5 0.011). Again, this is likely due to of these factors and also, after adjusting for possible
informative censoring, to determine whether the declinethe fact that all of the PD patients have their GFR values
routinely checked, while the selected HD patients may in GFR is similar between patients starting dialysis on
PD versus those starting on HD.have had limited follow-up with respect to their GFR
measurements. Moreover, for many of the HD patients, Two separate analyses of the data were performed.
The first analysis was based on all patients excludingdata regarding the status of the patient, that is, mortality
(N 5 14/39), transfer to PD (N 5 3/39), and transplant the three HD patients who transferred out of HD. The
second analysis was restricted to only those patients who(N 5 10/39), were obtained well after the conclusion of
the study, thus creating somewhat of a gap between the either died, transferred treatment modality, or were
transplanted (that is, all patients lost to follow-up weretime they completed their study (that is, the date of their
last GFR measurement) and the time to the selected excluded). In both analyses, an initial reference model
was fit to the data that included interaction effects be-patient outcomes (that is, death, transfer to PD, trans-
plant). The distribution of patients (between the two tween treatment modality, cause of dropout, and time
to dropout. Various reduced models were then fit to thestudy groups) who were either lost to follow-up, died,
transferred to another dialysis modality, or transplanted data and compared against the reference model so as
to determine what effects, if any, patient dropout andis shown in Table 1.
An exponential decay model similar to that described treatment modality had on the decline of GFR. Results
from the two analyses are presented separately as partby Lysaght et al was used to fit GFR as a function of
time on dialysis [5]. For the ith patient, the model is given A and part B.
as follows:
GFRij 5 b0i exp(2b1i 3 tij) 1 eij RESULTS
Part A: Analysis of all patients excluding HD patientswhere GFRij is the measured GFR (mL/min) for the ith
who transferred out of HDpatient at the jth follow-up time, tij. b0i is the ith patient’s
estimated starting GFR at initiation of dialysis (mL/min). In this analysis, we examined the effect of treatment
modality on the decline in GFR adjusting for patientb1i is the patient’s decay rate parameter (month21) that
essentially describes the rate of decline in GFR, and dropout, including dropouts classified as lost to follow-
up. We did this by fitting the GFR data to the exponentialeij is random within-patient error. Nonlinear regression
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Table 3. Parameter estimates and standard errors from a nonlinear mixed-effects model relating glomerular filtration rate (GFR) to
treatment modality adjusted for cause of dropout and time to dropout
Treatment modality
PD HD
Estimated relation to Estimated relation to
Parameter Cause of dropout dropout time, Ti dropout time, Ti P value
b0i mL/min Censoreda b0i 5 5.86 b0i 5 3.03 ,0.01
Died b0i 5 3.79 1 0.02404 3 Ti b0i 5 3.96 2 0.00004 3 Ti 0.716
Transferred b0i 5 5.27 2 0.02792 3 Ti —
Transplanted b0i 5 9.43 2 0.24752 3 Ti b0i 5 7.18 2 0.23028 3 Ti 0.357
b1i month21 Censoreda b1i 5 0.021 b1i 5 0.055 0.094
Died b1i 5 0.058 2 0.0007 3 Ti b1i 5 0.121 2 0.0007 3 Ti ,0.001
Transferred b1i 5 0.026 2 0.0002 3 Ti
Transplanted b1i 5 0.144 2 0.0058 3 Ti b1i 5 0.110 2 0.0051 3 Ti 0.754
Abbreviations are: PD, peritoneal dialysis; HD, hemodialysis.
a Among censored patients (i.e., patients lost to follow-up), there was no significant effect due to dropout time, and therefore those data were not included in the
reduced model
decay model shown previously, but with a patient’s start- tients; however, the relationship between their time to
dropout and the rate of decline in GFR may be strongering GFR, b0i, and decay rate, b1i, both modeled as a func-
tion of the patient’s treatment modality, cause of drop- or weaker than that observed for the PD patients. By
out, and time to dropout. Because of the small number including the cause of dropout and time to dropout as
of patients involved, we elected to exclude from this modality-specific covariates in the model, we can esti-
analysis the three HD patients who changed treatment mate and compare the decline in GFR over time between
modality. Patients were classified as lost to follow-up if PD and HD in a way that adjusts for any differential
they had not died, received a transplant, or changed effects caused by dropout between the two modalities.
modality during the course of follow-up. It is anticipated After fitting the previously mentioned reference
that missing values of GFR on these patients may be model to the data, we evaluated what effects age, diabe-
treated as missing at random (that is, are not related to tes, hypertension, and time to dropout had on GFR. This
their length of follow-up), but to test this, we included was done by comparing results from the reference model
their time to dropout (defined as the length of follow- to results from several reduced models in which age,
up) as a covariate in the initial reference model. While diabetes, and hypertension were removed, and in which
complicated, this model may be interpreted as follows. various specifications of the effect of dropout time were
In terms of the starting GFR parameter b0i, the model modeled. Based on a likelihood ratio test, there was no
simply states that among patients grouped according to significant effect of age, diabetes, or hypertension on
treatment modality and cause of dropout (for example, either the starting GFR or on the rate of decline in GFR
PD patients who transfer to HD), each patient has a (P . 0.48). In addition, we found that among patients
starting GFR that is linearly related to his/her dropout classified as lost to follow-up, there was no significant
time via the simple linear regression equation association between time to dropout (that is, length of
follow-up) and starting GFR, nor was there a significant
b0i 5 intercept 1 (slope 3 Ti) association between time to dropout and the decay rate
(P . 0.52). Consequently, we fit the data to a reducedwhere Ti is the time to dropout for the ith patient. Simi-
larly, the decay rate describing the rate of decline in model that excludes age, diabetes, and hypertension, and
that excludes the effect of dropout times among patientsGFR is also assumed to be linearly related to a patient’s
dropout time. By relating a patient’s time to dropout to lost to follow-up. Using this reduced model, we com-
pared the starting GFR (b0i in mL/min) and decay ratehis/her starting GFR and to his/her decay rate, we can
effectively test whether there is any informative censor- (b1i in months21) between PD and HD patients according
to their cause of dropout (death, PD transfer only, trans-ing of the data. For example, PD patients who drop out
early may be more likely to experience a rapid decline plant, lost to follow-up), and time to dropout. The results
of this analysis are summarized in Table 3 and are pre-in GFR than PD patients who stay on therapy longer.
If we were to ignore this relationship, then any estimate sented graphically in Figures 1 to 4. Among those pa-
tients who died, there was no significant difference in theobtained of the average rate of decline in GFR among
PD patients would be biased, since too much weight starting GFR between PD and HD (P 5 0.716; Fig. 1).
Similarly, there was no significant difference in startingwould be given to those patients who remain on therapy
longer. A similar phenomenon may exist for HD pa- GFR values between those PD and HD patients who
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Fig. 1. Comparison of estimated starting GFR by therapy, cause of
Fig. 3. Comparison of estimated starting GFR by therapy, cause of drop-dropout, and time to dropout. Symbols are: (n) peritoneal dialysis
out, and time to dropout. Symbols are: (n) peritoneal dialysis (PD);(PD); (d) hemodialysis (HD); dashed lines, PD transplant vs. HD
(d) hemodialysis (HD); solid lines, PD censored vs. HD censored,transplant, P 5 0.3567; solid lines, PD death vs. HD death, P 5 0.7161.
P 5 0.01.
Fig. 2. Comparison of percent decline in GFR per month by therapy, Fig. 4. Comparison of percent decline in GFR per month by therapy,
cause of dropout, and time to dropout. Symbols are: (n) peritoneal cause of dropout, and time to dropout. Symbols are: (n) peritoneal
dialysis (PD); (d) hemodialysis (HD); dashed lines, PD transplant vs. HD dialysis (PD); (d) hemodialysis (HD); dashed lines, HD death vs. PD
transplant, P 5 0.7540; solid lines, PD death vs. HD death, P 5 0.001. transfer, P 5 0.01; solid lines, HD censored vs. PD censored, P 5 0.094.
later received a transplant (P 5 0.357; Fig. 1). However, between those PD patients who transferred versus those
HD patients who died (P , 0.01; Fig. 4).among censored patients lost to follow-up, those patients
on PD had a significantly higher starting GFR than their
Part B: Analysis of all patients excluding thoseHD counterparts (P , 0.01; Fig. 3). In terms of the decay
lost to follow-uprate parameter b1i, we found that among patients who
died, those treated with PD had a significantly lower Following the suggestion of Follmann and Wu [19]
decay rate (that is, better preservation of GFR) than and Hogan and Laird [20], we fit the exponential decay
those treated with HD (P , 0.001; Fig. 2). There was model for only those patients who died, who were trans-
no statistically significant difference in the decay rate ferred to another modality, or who were transplanted.
between PD and HD patients who dropped out because The reason was that unlike those patients who were lost
of transplantation (P 5 0.754; Fig. 2). Likewise, there to follow-up, the exact time to dropout was known for
was no significant difference in the decay rate between these patients. The initial reference model included in-
PD and HD patients having censored dropout times, teractions between treatment modality, cause of drop-
although the results favored patients on PD (P 5 0.094; out, and time to dropout so as to determine whether the
Fig. 4). In addition to the comparisons shown in Table effect of dropout on the rate of decline in GFR depended
3, the rate of decline in GFR between PD patients who on the treatment modality. We also included the effects
transferred versus HD patients who were lost to follow- of age, diabetes, and hypertension to determine whether
up, died, or received a transplant were compared. In all they had any effect on the rate of decline in GFR. We
three cases, PD patients who transferred to HD had compared this reference model to several reduced models
better preservation of GFR (that is, a lower adjusted in which age, diabetes, and hypertension were dropped
from the model and where various specifications of themean decay rate) than any of the three HD groups,
although this better preservation was only significant effect of treatment modality were included to determine
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Table 4. Parameter estimates and standard errors from a nonlinear mixed-effects model relating glomerular filtration rate (GFR) to treatment
modality adjusted for cause of dropout and time to dropout
Treatment modality
PD HD
Estimated relation to Estimated relation to
Parameter Cause of dropout dropout time, Ti dropout time, Ti P value
b0i
a mL/min Died or transferred b0i 5 4.40 1 0.0004 3 Ti b0i 5 4.40 1 0.0004 3 Ti NAa
Transplant b0i 5 8.29 2 0.2405 3 Ti b0i 5 8.29 2 0.2405 3 T1 NAa
b1i month21 Died or transferred b1i 5 0.054 2 0.0007 3 Ti b1i 5 0.116 2 0.0007 3 Ti 0.0001
Transplant b1i 5 0.132 2 0.0057 3 Ti b1i 5 0.124 2 0.0057 3 Ti 0.7757
Results are restricted to only those patients who died, changed modality or were transplanted.
a Mean starting GFR (b0i) was not modeled as a function of treatment modality because preliminary tests showed no difference in starting GFR between peritoneal
dialysis (PD) and hemodialysis (HD) (P 5 0.87)
Fig. 5. Observed and predicted GFR for those patients who died or Fig. 6. Observed and predicted GFR for those patients who died or
changed modality within the first two years after the start of dialysis. changed modality two to four years after the start of dialysis. The pre-
The predicted GFR response profiles correspond to a patient having dicted GFR response profiles correspond to a patient having an average
an average time to dropout of 12.2 months, which is the average dropout time to dropout of 33.4 months, which is the average dropout time
time among those patients who died or changed modality within 0 to 2 among those patients who died or changed modality within 2 to 4 years
years following the start of dialysis. Symbols are: (h) observed HD; (solid following the start of dialysis. Symbols are: (h) observed HD; (solid
line) predicted HD; (d) observed PD; (dashed line) predicted PD. line) predicted HD; (d) observed PD; (dashed line) predicted PD.
rate of decline in GFR over time. More importantly, thisif treatment modality had an independent effect on GFR.
Each of the analyses showed there was no difference in result indicates that treatment modality is an indepen-
dent predictor of GFR in that its effect on the rate ofGFR profiles between those who died and those who
changed treatment modality, but both of these groups decline in GFR is independent of the cause of dropout
and of the time to dropout, both of which are importantwere found to differ from those patients who received a
transplant. Furthermore, there was no evidence of any sig- predictors of GFR. Specifically, when adjusted for time
to dropout, we found that patients on PD who died ornificant difference in the mean starting GFR between HD
and PD patients regardless of outcome. Consequently, were transferred to HD had a significantly better preserva-
tion of GFR over time (that is, a lower decay rate) thanthe type of dropouts were collapsed into two groups,
those who died/transferred and those who were trans- those HD patients who died or were transferred to PD
(P , 0.0001). There was no difference in the rate of de-planted. The final reduced model compared the rate of
decline in GFR between PD and HD adjusting for cause cline in GFR between PD and HD patients receiving a
transplant (P 5 0.7757). These results are graphicallyof dropout (death/transfer vs. transplant) and time to
dropout. We excluded the effects of age, diabetes, and displayed in Figures 5 to 8. Each graph compares the
observed GFR averaged over successive three-monthhypertension, as these had no significant effect on the
rate of decline in GFR. Table 4 presents the parameter periods versus the average GFR predicted from the
model. The graphs are divided according to the causeestimates for this final reduced model. Using a likelihood
ratio test, there was no difference between the full refer- of dropout (death/transfer vs. transplant) and time to
dropout (0 to 2 years, 2 to 4 years, 41 years).ence model and the reduced model shown in Table 4
(P 5 0.86953), which suggests that, for this particular In addition to the preceding results, there was no evi-
dence of any association between the time to dropout andpatient population, age, diabetes, and hypertension are
not predictive of the starting level of GFR nor of the the starting GFR among patients who died or changed
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Fig. 8. Observed and predicted GFR for those patients who receivedFig. 7. Observed and predicted GFR for those patients who died or
a transplant within the first two years after the start of dialysis. Thechanged modality four or more years after the start of dialysis. The
predicted GFR response profiles correspond to a patient having anpredicted GFR response profiles correspond to a patient having an
average time to dropout of 10.8 months, which is the average dropoutaverage time to dropout of 66.3 months, which is the average dropout
time among those patients who received a transplant within 0 to 2 yearstime among those patients who died or changed modality within four
following the start of dialysis. Symbols are: (h) observed HD; (solidor more years following the start of dialysis. Symbols are: (h) observed
line) predicted HD; (d) observed PD; (dashed line) predicted PD.HD; (solid line) predicted HD; (d) observed PD; (dashed line) pre-
dicted PD.
rate of decline between PD and HD is estimated to be
modality (P 5 0.9777). However, the results do suggest 69% [(0.070–0.022)/0.070 5 0.69], which is somewhat
that transplant (dialysis) patients who wait longer to re- higher than the 50% difference seen by Lysaght et al
ceive a transplant are likely to have a lower starting GFR (an estimated HD decay rate of 0.058 months21 vs. an
than those who receive their transplant relatively sooner estimated PD decay rate of 0.029 months21) [5].
(P 5 0.0204). The possible reasons behind this observa-
tion are unclear. It appears unlikely that the preemptive
DISCUSSIONdialysis of living transplants (leading to optimization of
The results from GFR data collected at the Universitypatient’s medical condition and a better preservation of
of Missouri-Columbia indicate that even after adjustingGFR due to comparatively earlier initiation of dialysis)
for dropouts caused by death, change in modality or trans-could have resulted in this observation, since only one
plantation, patients starting on PD have significantly bet-living unrelated transplant was performed among all the
ter preservation of GFR than patients starting on HD.patients who underwent renal transplantation. Also,
However, some caution regarding these results is war-dropout times (that is, times to death, times to transfer,
ranted. First and foremost, the HD patients were partor times to transplant) were significantly associated with
of a specific study protocol at the University of Missouri-the rate of decline in GFR in so far as patients with longer
Columbia and hence may not be representative of thedropout times had, on average, a better preservation of
general HD population in this center. In contrast, theGFR regardless of the cause of dropout (P , 0.0388).
GFR data, which are routinely collected for all PD pa-Since certain groups of patients exhibited a significant
tients at the University of Missouri-Columbia, do corre-correlation between their time to dropout and rate of
spond to this center’s overall PD population. This maydecline in GFR (Figs. 2 and 4), it was difficult to represent
explain why the HD and PD patients reported here differa single decay rate for HD versus PD. However, by
with respect to their underlying cause of ESRD (Tableconsidering what the GFR profile is for patients who
1). More importantly, this may explain why there wasexhibit the average characteristics of the study popula-
limited follow-up of GFR data on the HD patients (nonetion, we can estimate an average decay rate using the
of the HD patients had recorded GFR values of 0 in thisresults presented in Table 4. To that end, among those
study compared with 15 of the 102 PD patients havingpatients who dropped out, 79% either died or changed
recorded GFR values of 0, P 5 0.011). Such limitedmodality, while the remaining 21% received a transplant.
follow-up may itself bias the results, since there are noIn addition, the average time to dropout was estimated
GFR data reported past 24.9 months for the HD patients.to be 27.3 months (as computed from a product-limit
As a partial and informal check of this hypothesis, welife-table analysis of all participating patients including
those who were randomly censored). Combining these reanalyzed the data in part B of our analysis by restricting
follow-up for the PD patients to 25 months. The resultsvalues, we estimated the average decay rate to be 0.070
months21 for patients starting HD versus 0.022 months21 are very similar to those shown in Table 4, indicating
that the results are not unduly influenced by the longerfor patients starting PD.
From this, the percentage difference in the average periods of follow-up seen for the PD patients (Table 5).
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Table 5. Parameter estimates and standard errors from a nonlinear mixed-effects model relating glomerular filtration rate (GFR) to treatment
modality adjusted for cause of dropout and time to dropout
Treatment modality
PD HD
Estimated relation to Estimated relation to
Parameter Cause of dropout dropout time, Ti dropout time, Ti P value
b0i
a mL/min Died or transferred b0i 5 4.61 2 0.0077 3 Ti b0i 5 4.61 2 0.0077 3 Ti NAa
Transplant b0i 5 8.29 2 0.2404 3 Ti b0i 5 8.29 2 0.2404 3 Ti NAa
b1i month21 Died or transferred b1i 5 0.067 2 0.0012 3 Ti b1i 5 0.148 2 0.0012 3 Ti 0.0001
Transplant b1i 5 0.132 2 0.0056 3 Ti b1i 5 0.124 2 0.0056 3 Ti 0.7773
Results are restricted to only those patients who died, changed modality or were transplanted. Estimates presented here are based on restricting GFR follow-up
to 25 months for both HD and PD patients.
a Mean starting GFR (b0i) was not modeled as a function of treatment modality because preliminary tests showed no difference in starting GFR between peritoneal
dialysis (PD) and hemodialysis (HD) (P 5 0.87)
This does not rule out the possibility that by excluding that any analysis of GFR and its comparison between
HD and PD also take into account the phenomenonextended follow-up data from the HD patients, the rate
of decline in GFR may be overestimated in this study. of informative censoring apart from a variety of other
confounding factors like age, sex, race, comorbidity, na-Furthermore, there may be other factors not included in
this analysis that may explain our present findings. For ture of renal disease, use of nephrotoxic drugs, and effect
of dialysis modality.example, unmeasured comorbid conditions and/or disease
severity, dialysis dose, nutritional status, and the use of Rottembourg et al were the first to compare the main-
tenance of RRF between PD and HD [1, 2]. They re-nephrotoxic agents may explain a faster rate of decline
in HD patients who died or transferred. ported that CCr remained significantly higher in PD pa-
tients than in matched patients on HD. In addition, theMany patients on PD do maintain GFR above 2.0
mL/min beyond 2.5 years of therapy. RRF contributes urine output remained stable in PD patients, unlike the
HD patients who had a progressive decline in the urinea number of positive physiologic benefits to patients on
dialysis [6]. Small solute clearances provided by RRF output. Over a two-year period, similar results were re-
ported in a group of diabetic PD and HD patients [3].comprise a significant proportion of the total small solute
clearances over the first two years of the therapy [15]. In 1986, Cancarini et al published observations on PD
and HD patients in whom diuretics were not used and inHigher RRF at the initiation of dialysis and while on renal
replacement therapy have documented an improvement whom antihypertensive drug usage was equal [4]. In a
retrospective study looking at RRF in 55 PD patientsin outcomes and reduced patient mortality [14, 21, 22].
The issue of examining preservation of RRF in pa- and 57 HD patients, Lysaght et al analyzed the effect of
associated comorbidities on RRF in these patients [5].tients on dialysis is equally, if not more complex than the
analysis of mortality between PD and HD. The decline of This study looked at a minimum of four measurements
of RRF during the course of follow-up. In patients withRRF on dialysis has been reported to be slower in PD
than HD. However, some clinicians have questioned diabetic or other forms of glomerulopathies, the differ-
ence was highly significant (P , 0.001) and remained sowhether this reported difference in the rate of decline
of RRF might not be caused by selection bias. In particu- after correcting for other potential other risk factors,
that is, age, gender, hypertensive status, and the use oflar, if CAPD delivers only marginally adequate therapy
as some clinicians speculate, then perhaps those patients angiotensin-converting enzyme inhibitors. Differences
between cohorts for patients with other etiologies ofon CAPD with low GFR are purposefully switched to HD.
This is particularly problematic if one then censors pa- renal failure were not significant, however. There was
an exponential decline of RRF in both groups; the ratetients at the time of transfer from PD to HD from analysis
(that is, these patients are no longer followed in the of decline in HD patients was twice that of PD patients
(the monthly rate of decline in RRF was 2.9% on PDstudy once they have switched treatment modalities). If
patient dropout is indeed related to the rate of decline and 5.8% in HD patients).
Several hypothetical reasons have been cited for thein GFR and if this relationship differs between PD and
HD but is ignored in the analysis, then the results of apparently better preservation of GFR in patients on PD.
Unlike PD patients, HD patients experience a constantlysuch analysis may be biased. When this occurs, the data
are said to be informatively censored, a term used by changing hemodynamic environment [6]. HD generates
nephrotoxic inflammatory mediators [7, 11, 13], removesstatisticians to describe any kind of systematic bias asso-
ciated with censored or incomplete data (discussed pre- GFR stimulatory factors [23], and removes osmotic drive
[8]. In HD, generation of nephrotoxic cytokines by bio-viously in this article). It therefore becomes imperative
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incompatible dialyzer membranes has also been cited as mix adjustment as well as adjustment for informative
one of the reasons for a faster decline of RRF in such censoring will help us to understand this complex issue
patients. The benefits of HD with biocompatible mem- better. Such a study will enable us to determine whether
branes over HD with nonbiocompatible membranes are the effect of informative censoring is the same between
subject to some controversy [7, 9, 11, 12]. In patients on the two modalities. Until such a trial is done, drawing
PD, the modality of PD has also been reported to affect any firm conclusions regarding RRF and the better pres-
RRF. Some authors have reported a faster decline of ervation thereof (on PD) should be tempered.
RRF in automated PD possibly because of its intermit- There is a clear need to do a well-designed prospective
tent nature (APD) [24]. However, this issue is still to be longitudinal study of incident PD and HD patients in which
settled in large multicenter studies. In our study, the PD detailed baseline measurements and systematic follow-
population consisted predominantly of CAPD patients up of GFR values and patient outcomes are recorded in
(CAPD, 80%; APD, 20%). In view of the relatively small order to assess fully what effect treatment modality has
numbers, we did not assess the impact of modality of PD on the preservation of GFR.
on the decline of RRF separately in our study. The differ-
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